Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Authors :: Matthew J. Reilley
Luis M Vence
Funda Meric-Bernstam
Padmanee Sharma
Joann Lim
Ann Marie Bailey
Apostolia Maria Tsimberidou
Vivek Subbiah
David S. Hong
Aung Naing
Gerald Steven Falchook
Sandra Montez
Allison Bass
Daniel D. Karp
James P. Allison
Siqing Fu
Ralph Zinner
Sarina Anne Piha-Paul
Stacie Bean
Filip Janku
Source :: Journal of Clinical Oncology. 34:3054-3054
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 3054Background: Imatinib mesylate can induce rapid tumor regression, inhibit tumor immunosuppressive mechanisms, and release large amounts of antigenic debris from tumor cell death with subsequent ...

Tools